natgillin/translations-raw huggingface dataset:
STATEMENT OF ACTIVE SUBSTANCE(S) Each pre-filled multidose pen delivers 300 IU follitropin alfa, equivalent to 22 micrograms, per 0.5 mL. 
En napolnjen večodmerni injekcijski peresnik zagotavlja odmerek 300 i.e. folitropina alfa, kar ustreza 22 mikrogramom, v 0,5 ml. folitropin alfa, 600 i.e./ml (kar ustreza 44 mikrogramom/ml)
MARKETING AUTHORISATION NUMBER EU/1/95/001/035 
ŠTEVILKA DOVOLJENJA ZA PROMET Z ZDRAVILOM EU/1/95/001/035
• 1 sharp container 
• 1 posoda za ostre predmete
Contains: One pre-filled syringe of solvent contains: 0.75 mL water for injections, benzyl alcohol 
Vsebuje: Ena napolnjena injekcijska brizga z vehiklom vsebuje 0,75 ml vode za injekcije, 0,9 % benzilalkohol.
STATEMENT OF ACTIVE SUBSTANCE(S) Each pre-filled multidose pen delivers 450 IU follitropin alfa, equivalent to 33 micrograms, per 0.75 mL. 
En napolnjen večodmerni injekcijski peresnik zagotavlja odmerek 450 i.e. folitropina alfa, kar ustreza 33 mikrogramom, v 0,75 ml. folitropin alfa, 600 i.e./ml (kar ustreza 44 mikrogramom/ml)
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) solution for injection in pre-filled pen. 
GONAL-f 450 i.e./0,75 ml (33 mikrogramov/0,75 ml) raztopina za injiciranje v napolnjenem injekcijskem peresniku
if "0", injectioncomplete ifnot"0",needsecond injection 
Če je "0", je injiciranje končano
Sodium dihydrogen phosphate monohydrate Disodium phosphate dihydrate Methionine 
Prašek saharoza natrijev dihidrogenfosfat monohidrat natrijev hidrogenfosfat dihidrat metionin polisorbat 20 fosforjeva (V) kislina, koncentrirana natrijev hidroksid
PARTICULARS TO APPEAR ON THE PEN GONAL-f 900 IU/1.5 mL 
PODATKI NA NAPOLNJENEM INJEKCIJSKEM PERESNIKU GONAL-f 900 i.e./1,5 ml
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS GONAL-f 1050 IU/1.75 ML (77 MICROGRAMS/1.75 ML), VIAL LABEL 
GONAL-F 1050 I.E./1,75 ML (77 MIKROGRAMOV/1,75 ML) NALEPKA NA VIALI
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS GONAL-f 300 IU/0.50 ML (22 MICROGRAMS/0.50 ML), VIAL LABEL 
GONAL-F 300 I.E./0,50 ML (22 MIKROGRAMOV/0,50 ML) NALEPKA NA VIALI
PHARMACEUTICAL FORM AND CONTENTS Solution for injection in a pre-filled pen. 
FARMACEVTSKA OBLIKA IN VSEBINA Raztopina za injiciranje v napolnjenem injekcijskem peresniku 1 večodmerni napolnjen injekcijski peresnik 12 injekcijskih igel
How to use the GONAL-f pre-filled pen 
Uporaba GONAL-f napolnjenega injekcijskega peresnika
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS GONAL-f 450 IU/0.75 ML (33 MICROGRAMS/0.75 ML), VIAL LABEL 
GONAL-F 450 I.E./0,75 ML (33 MIKROGRAMOV/0,75 ML) NALEPKA NA VIALI
900IU 
900i.e.
NAME OF THE MEDICINAL PRODUCT GONAL-f 300 IU/0.5 mL (22 micrograms/0.5 mL) solution for injection in pre-filled pen. 
GONAL-f 300 i.e./0,5 ml (22 mikrogramov/0,5 ml) raztopina za injiciranje v napolnjenem injekcijskem peresniku
300IU 
300i.e.
Talk to your doctor immediately, 
Nemudoma se pogovorite s svojim zdravnikom
See also further information in this section under “Warnings and precautions” and “Pregnancy, contraception and breast-feeding”. 
Glejte tudi dodatne informacije v tem poglavju pod "Opozorila in previdnostni ukrepi" in "Nosečnost, kontracepcija in dojenje".
50 tablets 150 tablets 50 x 1 tablets 
50 tablet 150 tablet 50 x 1 tablet
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
• Redno posodobljena poročila o varnosti zdravila Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
EU/1/07/439/003 (50 tablets) EU/1/07/439/004 (150 tablets) EU/1/07/439/005 (50 x 1 tablets) 
EU/1/07/439/003 (50 tablet) EU/1/07/439/004 (150 tablet) EU/1/07/439/005 (50 x 1 tablet)
Read the package leaflet before use. 
Za peroralno uporabo Pred uporabo preberite priloženo navodilo.
EU/1/07/439/001 (100 capsules) EU/1/07/439/002 (300 capsules) EU/1/07/439/006 (100 x 1 capsules) 
EU/1/07/439/001 (100 kapsul) EU/1/07/439/002 (300 kapsul) EU/1/07/439/006 (100 x 1 kapsula)
• if you are not using effective contraception (see Pregnancy, contraception and breast-feeding). 
• če ne uporabljate učinkovite kontracepcije (glejte Nosečnost, kontracepcija in dojenje), • če dojite.
• Nervous system malformations such as spina bifida; 
• malformacije živčnega sistema, kot je spina bifida,
• if you are allergic to mycophenolate mofetil, mycophenolic acid or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na mofetilmikofenolat, mikofenolno kislino ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times. 
Če ste pozabili vzeti zdravilo Mofetilmikofenolat Teva Če ste pozabili vzeti zdravilo, ga vzemite takoj, ko se spomnite, in nato nadaljujte kot običajno.
The Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme and a follow-up pregnancy questionnaire, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority. 
Imetnik dovoljenja za promet se mora z nacionalnim organom, pristojnim za zdravila, dogovoriti o vsebini in obliki izobraževalnega programa in vprašalnika o spremljanju nosečnosti, vključno s komunikacijskim medijem, načinom distribucije in vsemi drugimi vidiki programa.
The risk of bronchiectasis may be linked to hypogammaglobulinaemia or to a direct effect on the lung. 
Tveganje za bronhiektazo je lahko povezano s hipogamaglobulinemijo ali z neposrednim učinkom na pljuča.
• You are a child or teenager who has not started having periods. 
- Če ste otrok/najstnica, ki še ni dobila prve menstruacije.
Medicinal products that interfere with enterohepatic circulation (e.g. cholestyramine, ciclosporin A, antibiotics) 
Zdravila, ki vplivajo na enterohepatični obtok (npr. holestiramin, ciklosporin A, antibiotiki)
There have also been reports of bronchiectasis in children and adults (frequency not known). 
Poročali so o primerih bronhiektaze pri otrocih in odraslih (pogostnost ni poznana).
Non-melanoma skin carcinomas occurred in 3.6% of patients; other types of malignancy occurred in 1.1% of patients. 
bolnikov so opazili nemelanomski kožni rak, druge vrste malignosti pa so se pojavile pri 1,1 % bolnikov.
It is recommended, however, to administer Mycophenolate mofetil Teva at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption of MPA. 
Vseeno je priporočljivo, da dajemo zdravilo Mofetilmikofenolat Teva vsaj eno uro pred ali tri po dajanju sevelamerja, zato da zmanjšamo vpliv na absorpcijo mikofenolne kisline.
The educational programme is aimed at ensuring that the health professionals and patients are aware of the teratogenicity and mutagenicity, the need for pregnancy tests before starting therapy with 
Namen izobraževalnega programa je zagotoviti, da bi se zdravstveni delavci in bolniki zavedali teratogenosti in mutagenosti, potrebe po testih nosečnosti pred začetkom zdravljenja z zdravilom Mofetilmikofenolat Teva,
The MAH shall ensure that in each MS where Mycophenolate mofetil Teva is marketed, all healthcare professionals and patients who are expected to prescribe, dispense or use Mycophenolate mofetil Teva are provided with the following educational package: 
Imetnik dovoljenja za promet mora zagotoviti, da v vseh državah članicah, kjer je zdravilo Mofetilmikofenolat Teva na tržišču, vsi zdravstveni delavci in bolniki, za katere se pričakuje, da bodo predpisovali, izdajali ali uporabljali zdravilo Mofetilmikofenolat Teva, prejeli naslednja izobraževalna gradiva:
It is recommended to monitor MPA exposure levels and to adjust Mycophenolate mofetil Teva doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly. 
Priporočljivo je spremljanje ravni izpostavljenosti mikofenolni kislini in prilagoditev odmerkov zdravila Mofetilmikofenolat Teva za ohranitev klinične učinkovitosti, kadar sočasno dajemo rifampicin.
Patients taking Mycophenolate mofetil Teva should have complete blood counts weekly during the first month, twice monthly for the second and third months of treatment then monthly through the first year. 
Med zdravljenjem z zdravilom Mofetilmikofenolat Teva moramo napraviti preiskave celotne krvne slike enkrat na teden prvi mesec, dvakrat mesečno v drugem in tretjem mesecu in nato enkrat mesečno v prvem letu.
• bacterial infections usually resulting in a serious lung disorder (tuberculosis, atypical mycobacterial infection) 
• bakterijske okužbe, ki običajno povzročijo resno pljučno bolezen (tuberkuloza, atipična mikobakterijska okužba)
MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. 
nekompetitivni in reverzibilni zaviralec inozin-monofosfat-dehidrogenaze in tako zavira de novo sintezo gvanozinskih nukleotidov, brez vključevanja v DNA.
Stopping your treatment with Mycophenolate mofetil Teva may increase the chance of rejection of your transplanted organ. 
Prenehanje zdravljenja z zdravilom Mofetilmikofenolat Teva lahko poveča možnost zavrnitve vašega presadka.
The usual way to take Mycophenolate mofetil Teva is as follows: 
Običajen način jemanja zdravila Mofetilmikofenolat Teva je naslednji:
Very common (may affect more than 1 in 10 people) 
Drugi neželeni učinki Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov)
Treatment with Mycophenolate mofetil Teva should be initiated and maintained by appropriately qualified transplant specialists. 
Zdravljenje z zdravilom Mofetilmikofenolat Teva mora vpeljati in voditi ustrezen specialist za presaditve.
Agranulocytosis (≥1/1000 to <1/100) and neutropenia have been reported; therefore regular monitoring of patients taking Mycophenolate mofetil Teva is advised (see section 4.4). 
Poročali so tudi o agranulocitozi (≥ 1/1000 do < 1/100) in nevtropeniji, zato je priporočljivo bolnike, ki jemljejo zdravilo Mofetilmikofenolat Teva, redno spremljati (glejte poglavje 4.4).
What Mycophenolate mofetil Teva is and what it is used for 
Kaj je zdravilo Mofetilmikofenolat Teva in za kaj ga uporabljamo
• You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have treatment for cancer, then there is still a chance you could become pregnant). 
Med ženske, ki ne morejo zanositi, sodite, če karkoli od naslednjega velja za vas: - Če ste v postmenopavzi, torej stari vsaj 50 let in ste imeli zadnjo menstruacijo pred več kot 1 letom (če menstruacije niste imeli, ker ste se zdravili zaradi raka, še vedno obstaja možnost, da zanosite).
In the early post-transplant period (<°40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 - 6°months post-transplant). 
V zgodnjem obdobju po presaditvi (do 40. dneva po presaditvi) je srednja AUC mikofenolne kisline pri bolnikih z ledvičnim, srčnim ali jetrnim presadkom za približno 30 % manjša, Cmax pa za približno 40 % manjša v primerjavi s poznejšim obdobjem po presaditvi (3 do 6 mesecev po presaditvi).
It is used in combination with other medicines with a similar function (i.e. ciclosporin and corticosteroids). 
Zdravilo Mofetilmikofenolat Teva uporabljamo skupaj z drugimi zdravili s podobnim delovanjem (to so ciklosporin in kortikosteroidi).
• Your ovaries no longer work (premature ovarian failure, which has been confirmed by a specialist gynaecologist). 
- Če imate okvaro jajčnikov (prezgodnjo insuficienco jajčnikov), ki jo je potrdil specialist ginekolog.
Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported. 
Preobčutljivost Poročali so o preobčutljivostnih reakcijah, vključno z angionevrotičnim edemom in anafilaktično reakcijo.
Multidrug resistance protein 1 (MDR1) is also able to transport MPA, but its contribution seems to be confined to the absorption process. 
Protein za multiplo odpornost na zdravila 1 (MRP1 - Multidrug resistance protein 1) je prav tako lahko prenašalec mikofenolne kisline, vendar se zdi, da prispeva le k absorpciji.
Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome. 
Zdravila Mofetilmikofenolat Teva zato ne dajemo bolnikom z redkim dednim pomanjkanjem hipoksantin-gvaninfosforiboziltransferaze (HGPRT), kot sta Lesch-Nyhlanov in Kelley-Seegmillerjev sindrom.
Patients receiving Mycophenolate mofetil Teva should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression. 
Bolnikom, ki prejemajo zdravilo Mofetilmikofenolat Teva, je treba naročiti, da morajo takoj poročati o kakršnem koli znaku okužbe, nepričakovani modrici, krvavitvi ali drugih znakih depresije kostnega mozga.
• if you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage. 
• če ste bolnica, ki bi lahko bila noseča, in pred prvim predpisanim receptom nimate potrjenega negativnega testa nosečnosti, saj lahko mofetilmikofenolat povzroči prirojene okvare in spontani splav,
In some of these cases switching mycophenolate mofetil to another immunosuppressant resulted in improvement in respiratory symptoms. 
V nekaj od teh primerov je zamenjava mofetilmikofenolata za drugi imunosupresiv povzročila izboljšanje respiratornih simptomov.
• decrease in the number of white blood cells, platelets or red blood cells, which can result in increased risk of infections, bruising, bleeding, breathlessness and weakness 
• herpes, pasasti izpuščaj • zmanjšanje števila belih krvnih celic, trombocitov ali rdečih krvnih celic, ki lahko povzroči povečano tveganje za okužbe, modrice, krvavitve, zasoplost in šibkost.
• proliferation of the lymphatic tissue, including malignant tumours 
• rast limfatičnega tkiva, vključno z malignimi tumorji.
Mycophenolate mofetil Teva is an inosine monophosphate dehydrogenase (IMPDH) inhibitor. 
Zdravilo Mofetilmikofenolat Teva je zaviralec inozin-monofosfat-dehidrogenaze (IMPDH).
• if you experience any evidence of infection (e.g. fever, sore throat), unexpected bruising and/or bleeding. 
- če opazite znake okužbe (npr. zvišana telesna temperatura, vneto grlo), nepričakovane podplutbe in/ali krvavitve;
The first dose of oral Mycophenolate mofetil Teva will be given to you at least 4°days after the transplant operation and when you are able to swallow oral medicines. 
Odrasli Prvi peroralni odmerek zdravila Mofetilmikofenolat Teva boste prejeli vsaj 4 dni po presaditvenem posegu in takoj, ko boste lahko jemali zdravila peroralno.
Patients should be advised that during treatment with Mycophenolate mofetil Teva, vaccinations may be less effective and the use of live attenuated vaccines should be avoided (see section 4.5). 
Bolnike, ki prejemajo zdravilo Mofetilmikofenolat Teva, moramo opozoriti, da so lahko cepiva manj učinkovita, uporabi živih cepiv pa se morajo izogibati (glejte poglavje 4.5).
• Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil. 
• Pri nosečnicah, izpostavljenih mofetilmikofenolatu, so poročali o spontanih splavih pri 45 do 49 % bolnic v primerjavi z med 12 in 33 % pri bolnicah s presajenim solidnim organom, zdravljenih z drugimi imunosupresivi razen mofetilmikofenolata.
If neutropenia develops, dosing with Mycophenolate mofetil Teva should be interrupted or the dose reduced (see section 4.4). 
Če se pojavi nevtropenija, je treba odmerjanje zdravila Mofetilmikofenolat Teva prekiniti ali odmerek zmanjšati (glejte poglavje 4.4).
What you need to know before you take Mycophenolate mofetil Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Mofetilmikofenolat Teva
• Your fallopian tubes and both ovaries have been removed by surgery (bilateral salpingooophorectomy). 
- Če so vam z operacijo odstranili jajcevoda in oba jajčnika (bilateralna salpingo-ooforektomija).
Mycophenolate mofetil Teva should not be used at all in children under 2 years old. 
Zdravila Mofetilmikofenolat Teva se ne sme uporabljati pri otrocih, starih manj kot 2 leti.
Patients treated with immunosuppressants, including Mycophenolate mofetil Teva, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). 
Bolniki, ki se zdravijo z imunosupresivi, vključno z zdravilom Mofetilmikofenolat Teva, imajo povečano tveganje za oportunistične okužbe (bakterijske, glivične, virusne in protozojske), smrtne okužbe in sepso (glejte poglavje 4.8).
These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs. 
Ti podatki podpirajo ekstrapolacijo teh ugotovitev na vse antacide, saj je zmanjšanje izpostavljenosti, kadar je zdravilo Mofetilmikofenolat Teva sočasno uporabljeno z magnezijevimi in aluminijevi hidroksidi, občutno manjše v primerjavi s sočasno uporabo zdravila Mofetilmikofenolat Teva in zaviralcev protonske črpalke.
• Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits; 
• malformacije obraza, kot so razcep ustnice, razcep neba, mikrognatija in orbitalni hipertelorizem,
These changes may suggest a ‘left shift' in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive Mycophenolate mofetil Teva. 
Te spremembe lahko pri preiskavah krvi predstavljajo ‘premik v levo' pri zorenju nevtrofilcev, kar se lahko pri imunosupresiranih bolnikih, kot so ti, ki prejemajo zdravilo
• You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner`s syndrome or uterine agenesis. 
- Če ste se rodili z enim eno od naslednjih redkih stanj, zaradi katerih nosečnost ni mogoča: genotip XY,
Mycophenolate mofetil Teva is used in children and adolescents (aged 2 to 18) to prevent a body rejecting a transplanted kidney. 
Zdravilo Mofetilmikofenolat Teva se uporablja pri otrocih in mladostnikih (starih od 2 do 18 let) za preprečevanje zavrnitve presajene ledvice.
Mycophenolate mofetil Teva capsules should only be prescribed to patients with a body surface area of at least 1.25 m2. 
Kapsule zdravila Mofetilmikofenolat Teva lahko predpišemo samo bolnikom, katerih telesna površina je večja od 1,25 m2.
• high level of cholesterol and/or lipids in the blood 
• visoka raven sladkorja v krvi • visoka raven holesterola in/ali lipidov v krvi
Mycophenolate mofetil Teva has not been shown to impair your ability to drive or operate machines. 
Za zdravilo Mofetilmikofenolat Teva ni bilo pokazano, da vpliva na sposobnost za upravljanje vozil ali strojev.
Before starting Mycophenolate mofetil Teva treatment, women of childbearing potential must have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL in order to exclude unintended exposure of the embryo to mycophenolate. 
Da izključimo nenamerno izpostavljenost zarodka mofetilmikofenolatu, morajo bolnice v rodni dobi pred začetkom zdravljenja z zdravilom Mofetilmikofenolat Teva opraviti dva serumska ali urinska testa nosečnosti z občutljivostjo najmanj 25 mi.e./ml, ki morata biti negativna.
Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed Mycophenolate mofetil Teva capsules at a dose of 750 mg twice daily (1.5 g daily dose). 
Bolnikom s telesno površino med 1,25 in 1,5 m2 predpišemo kapsule zdravila Mofetilmikofenolat Teva v odmerku 750 mg dvakrat na dan (dnevni odmerek 1,5 g).
What Mycophenolate mofetil Teva is and what it is used for What you need to know before you take Mycophenolate mofetil Teva How to take Mycophenolate mofetil Teva Possible side effects 
Kaj je zdravilo Mofetilmikofenolat Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Mofetilmikofenolat Teva Kako jemati zdravilo Mofetilmikofenolat Teva
Mycophenolate mofetil Teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. 
Zdravilo Mofetilmikofenolat Teva je indicirano skupaj s ciklosporinom in kortikosteroidi za preprečevanje akutnih zavrnitvenih reakcij pri bolnikih z alogenim ledvičnim, srčnim ali jetrnim presadkom.
Patients receiving Mycophenolate mofetil Teva should be monitored for neutropenia, which may be related to Mycophenolate mofetil Teva itself, concomitant medicinal products, viral infections, or some combination of these causes. 
Bolnike, ki prejemajo zdravilo Mofetilmikofenolat Teva, je treba skrbno nadzorovati zaradi nevtropenije, ki je lahko posledica jemanja zdravila Mofetilmikofenolat Teva, sočasno uporabljenih zdravil, virusnih okužb ali nekaterih kombinacij teh vzrokov.
Patients should be instructed to consult their physician immediately should pregnancy occur. 
Bolnicam je treba svetovati, naj v primeru zanositve takoj obvestijo svojega zdravnika.
Hypersensitivity reactions to Mycophenolate mofetil Teva have been observed (see section 4.8). 
Opazili so preobčutljivostne reakcije na mofetilmikofenolat (glejte poglavje 4.8).
Mycophenolate is a powerful human teratogen. 
Teratogeni učinki Mofetilmikofenolat je močan humani teratogen.
• For 6°weeks after you stop taking Mycophenolate mofetil Teva. 
- 6 tednov po prenehanju jemanja zdravila Mofetilmikofenolat Teva.
Mycophenolate mofetil Teva should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1. 
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati pri bolnikih s preobčutljivostjo za mofetilmikofenolat, mikofenolno kislino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly (≥°65 years) has not been formally evaluated. 
Starejši bolniki Farmakokinetičnih parametrov mofetilmikofenolata pri starejših bolnikih (starih 65 let ali več) niso proučevali.
Caution should be used with medicinal products that interfere with enterohepatic circulation because of their potential to reduce the efficacy of mycophenolate mofetil. 
Pri uporabi zdravil, ki vplivajo na enterohepatični obtok, je potrebna previdnost, saj lahko zmanjšajo učinkovitost mofetilmikofenolata.
How to store Mycophenolate mofetil Teva Contents of the pack and other information 
Shranjevanje zdravila Mofetilmikofenolat Teva Vsebina pakiranja in dodatne informacije
Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in ≥1/10 and in 
Drugi neželeni učinki Neželeni učinki, ki so verjetno ali možno povezani z mofetilmikofenolatom in so se pojavili pri ≥1/10 in pri
Contents of the pack and other information What Mycophenolate mofetil Teva contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Mofetilmikofenolat Teva
In the kidney MPA and its metabolites potently interact with renal organic anion transporters. 
ledvicah pride do močne interakcije mikofenolne kisline in njenih metabolitov z ledvičnimi organskimi anionskimi prenašalci.